nodes	percent_of_prediction	percent_of_DWPC	metapath
Cabergoline—HTR2A—arteriole—atherosclerosis	0.011	0.105	CbGeAlD
Cabergoline—HTR7—vein—atherosclerosis	0.0105	0.0999	CbGeAlD
Cabergoline—HTR2A—vein—atherosclerosis	0.00656	0.0623	CbGeAlD
Cabergoline—HTR1B—artery—atherosclerosis	0.00556	0.0528	CbGeAlD
Cabergoline—HTR1D—artery—atherosclerosis	0.00538	0.0511	CbGeAlD
Cabergoline—HTR2A—hindlimb—atherosclerosis	0.00436	0.0414	CbGeAlD
Cabergoline—HTR1B—blood vessel—atherosclerosis	0.00433	0.0411	CbGeAlD
Cabergoline—HTR7—artery—atherosclerosis	0.00429	0.0407	CbGeAlD
Cabergoline—HTR1D—blood vessel—atherosclerosis	0.00419	0.0398	CbGeAlD
Cabergoline—HTR2A—appendage—atherosclerosis	0.00374	0.0355	CbGeAlD
Cabergoline—HTR7—endothelium—atherosclerosis	0.00362	0.0344	CbGeAlD
Cabergoline—HTR7—blood vessel—atherosclerosis	0.00334	0.0317	CbGeAlD
Cabergoline—Cramps of lower extremities—Niacin—atherosclerosis	0.00313	0.00676	CcSEcCtD
Cabergoline—Sleep disorder—Simvastatin—atherosclerosis	0.00312	0.00672	CcSEcCtD
Cabergoline—CYP3A4—Ezetimibe—atherosclerosis	0.0031	0.211	CbGbCtD
Cabergoline—CYP3A4—Rosuvastatin—atherosclerosis	0.0031	0.211	CbGbCtD
Cabergoline—Hepatic function abnormal—Simvastatin—atherosclerosis	0.00309	0.00666	CcSEcCtD
Cabergoline—Hot flush—Ezetimibe—atherosclerosis	0.00302	0.00652	CcSEcCtD
Cabergoline—Menopausal symptoms—Ezetimibe—atherosclerosis	0.003	0.00646	CcSEcCtD
Cabergoline—Abnormal vision—Niacin—atherosclerosis	0.00298	0.00642	CcSEcCtD
Cabergoline—Influenza—Rosuvastatin—atherosclerosis	0.00294	0.00634	CcSEcCtD
Cabergoline—CYP3A4—Simvastatin—atherosclerosis	0.00288	0.196	CbGbCtD
Cabergoline—Hepatic function abnormal—Niacin—atherosclerosis	0.00283	0.00611	CcSEcCtD
Cabergoline—Bronchitis—Rosuvastatin—atherosclerosis	0.00283	0.0061	CcSEcCtD
Cabergoline—Sleep disorder—Pravastatin—atherosclerosis	0.00282	0.00607	CcSEcCtD
Cabergoline—CYP3A4—Lovastatin—atherosclerosis	0.00282	0.192	CbGbCtD
Cabergoline—CYP3A4—Pravastatin—atherosclerosis	0.00282	0.192	CbGbCtD
Cabergoline—Hepatic function abnormal—Pravastatin—atherosclerosis	0.00279	0.00602	CcSEcCtD
Cabergoline—HTR2A—artery—atherosclerosis	0.00267	0.0254	CbGeAlD
Cabergoline—Depression—Rosuvastatin—atherosclerosis	0.00262	0.00564	CcSEcCtD
Cabergoline—Liver function test abnormal—Ezetimibe—atherosclerosis	0.00261	0.00563	CcSEcCtD
Cabergoline—Hot flush—Pravastatin—atherosclerosis	0.00261	0.00562	CcSEcCtD
Cabergoline—Menopausal symptoms—Pravastatin—atherosclerosis	0.00258	0.00557	CcSEcCtD
Cabergoline—Urinary tract infection—Rosuvastatin—atherosclerosis	0.00255	0.0055	CcSEcCtD
Cabergoline—Gastritis—Ezetimibe—atherosclerosis	0.0025	0.0054	CcSEcCtD
Cabergoline—Influenza—Lovastatin—atherosclerosis	0.00249	0.00537	CcSEcCtD
Cabergoline—Disturbance in sexual arousal—Niacin—atherosclerosis	0.00246	0.0053	CcSEcCtD
Cabergoline—Influenza—Ezetimibe—atherosclerosis	0.00245	0.00527	CcSEcCtD
Cabergoline—Face oedema—Niacin—atherosclerosis	0.00239	0.00516	CcSEcCtD
Cabergoline—Abdominal discomfort—Lovastatin—atherosclerosis	0.00239	0.00515	CcSEcCtD
Cabergoline—Gastritis—Simvastatin—atherosclerosis	0.00239	0.00515	CcSEcCtD
Cabergoline—Rhinitis—Rosuvastatin—atherosclerosis	0.00236	0.00509	CcSEcCtD
Cabergoline—Liver function test abnormal—Niacin—atherosclerosis	0.00229	0.00493	CcSEcCtD
Cabergoline—Upper respiratory tract infection—Ezetimibe—atherosclerosis	0.00227	0.0049	CcSEcCtD
Cabergoline—Orthostatic hypotension—Niacin—atherosclerosis	0.00226	0.00488	CcSEcCtD
Cabergoline—HTR2A—endothelium—atherosclerosis	0.00226	0.0214	CbGeAlD
Cabergoline—Liver function test abnormal—Pravastatin—atherosclerosis	0.00225	0.00486	CcSEcCtD
Cabergoline—Bronchitis—Simvastatin—atherosclerosis	0.00224	0.00483	CcSEcCtD
Cabergoline—Abdominal discomfort—Simvastatin—atherosclerosis	0.00224	0.00482	CcSEcCtD
Cabergoline—Upper respiratory tract infection—Simvastatin—atherosclerosis	0.00217	0.00467	CcSEcCtD
Cabergoline—Urinary tract infection—Lovastatin—atherosclerosis	0.00216	0.00466	CcSEcCtD
Cabergoline—HTR1D—connective tissue—atherosclerosis	0.00215	0.0204	CbGeAlD
Cabergoline—Influenza—Niacin—atherosclerosis	0.00214	0.00462	CcSEcCtD
Cabergoline—Influenza—Pravastatin—atherosclerosis	0.00211	0.00455	CcSEcCtD
Cabergoline—Arrhythmia—Rosuvastatin—atherosclerosis	0.0021	0.00453	CcSEcCtD
Cabergoline—ADRB1—connective tissue—atherosclerosis	0.00209	0.0198	CbGeAlD
Cabergoline—HTR2A—blood vessel—atherosclerosis	0.00208	0.0198	CbGeAlD
Cabergoline—Depression—Simvastatin—atherosclerosis	0.00207	0.00447	CcSEcCtD
Cabergoline—Bronchitis—Niacin—atherosclerosis	0.00206	0.00444	CcSEcCtD
Cabergoline—Sweating increased—Pravastatin—atherosclerosis	0.00205	0.00443	CcSEcCtD
Cabergoline—Flatulence—Rosuvastatin—atherosclerosis	0.00202	0.00435	CcSEcCtD
Cabergoline—Upper respiratory tract infection—Pravastatin—atherosclerosis	0.00196	0.00422	CcSEcCtD
Cabergoline—HTR1B—cardiovascular system—atherosclerosis	0.00193	0.0183	CbGeAlD
Cabergoline—Oedema peripheral—Ezetimibe—atherosclerosis	0.00193	0.00416	CcSEcCtD
Cabergoline—Weight increased—Pravastatin—atherosclerosis	0.00192	0.00414	CcSEcCtD
Cabergoline—Weight decreased—Pravastatin—atherosclerosis	0.00191	0.00411	CcSEcCtD
Cabergoline—Depression—Pravastatin—atherosclerosis	0.00187	0.00404	CcSEcCtD
Cabergoline—HTR1D—cardiovascular system—atherosclerosis	0.00187	0.0178	CbGeAlD
Cabergoline—Urinary tract infection—Pravastatin—atherosclerosis	0.00183	0.00394	CcSEcCtD
Cabergoline—ADRB1—cardiovascular system—atherosclerosis	0.00182	0.0173	CbGeAlD
Cabergoline—Alopecia—Lovastatin—atherosclerosis	0.00176	0.0038	CcSEcCtD
Cabergoline—Arthralgia—Rosuvastatin—atherosclerosis	0.00174	0.00376	CcSEcCtD
Cabergoline—HTR2B—cardiovascular system—atherosclerosis	0.00174	0.0165	CbGeAlD
Cabergoline—Alopecia—Ezetimibe—atherosclerosis	0.00173	0.00373	CcSEcCtD
Cabergoline—Rhinitis—Niacin—atherosclerosis	0.00172	0.0037	CcSEcCtD
Cabergoline—HTR7—connective tissue—atherosclerosis	0.00171	0.0163	CbGeAlD
Cabergoline—Flatulence—Lovastatin—atherosclerosis	0.00171	0.00369	CcSEcCtD
Cabergoline—Rhinitis—Pravastatin—atherosclerosis	0.00169	0.00365	CcSEcCtD
Cabergoline—Oedema peripheral—Niacin—atherosclerosis	0.00169	0.00364	CcSEcCtD
Cabergoline—Confusional state—Rosuvastatin—atherosclerosis	0.00169	0.00364	CcSEcCtD
Cabergoline—Back pain—Lovastatin—atherosclerosis	0.00168	0.00362	CcSEcCtD
Cabergoline—Flatulence—Ezetimibe—atherosclerosis	0.00168	0.00362	CcSEcCtD
Cabergoline—Muscle spasms—Lovastatin—atherosclerosis	0.00167	0.0036	CcSEcCtD
Cabergoline—Visual impairment—Niacin—atherosclerosis	0.00165	0.00356	CcSEcCtD
Cabergoline—Alopecia—Simvastatin—atherosclerosis	0.00165	0.00356	CcSEcCtD
Cabergoline—Back pain—Ezetimibe—atherosclerosis	0.00165	0.00355	CcSEcCtD
Cabergoline—Muscle spasms—Ezetimibe—atherosclerosis	0.00164	0.00353	CcSEcCtD
Cabergoline—Visual impairment—Pravastatin—atherosclerosis	0.00163	0.00351	CcSEcCtD
Cabergoline—Ill-defined disorder—Lovastatin—atherosclerosis	0.00161	0.00347	CcSEcCtD
Cabergoline—ADRB1—adipose tissue—atherosclerosis	0.0016	0.0152	CbGeAlD
Cabergoline—Flatulence—Simvastatin—atherosclerosis	0.0016	0.00345	CcSEcCtD
Cabergoline—Ill-defined disorder—Ezetimibe—atherosclerosis	0.00158	0.00341	CcSEcCtD
Cabergoline—Malaise—Lovastatin—atherosclerosis	0.00157	0.00338	CcSEcCtD
Cabergoline—Cardiac disorder—Pravastatin—atherosclerosis	0.00157	0.00338	CcSEcCtD
Cabergoline—Muscle spasms—Simvastatin—atherosclerosis	0.00156	0.00337	CcSEcCtD
Cabergoline—Vertigo—Lovastatin—atherosclerosis	0.00156	0.00336	CcSEcCtD
Cabergoline—HTR1A—cardiovascular system—atherosclerosis	0.00156	0.0148	CbGeAlD
Cabergoline—Malaise—Ezetimibe—atherosclerosis	0.00154	0.00331	CcSEcCtD
Cabergoline—HTR2B—adipose tissue—atherosclerosis	0.00153	0.0146	CbGeAlD
Cabergoline—Arrhythmia—Niacin—atherosclerosis	0.00153	0.0033	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.00152	0.00329	CcSEcCtD
Cabergoline—Alopecia—Niacin—atherosclerosis	0.00151	0.00327	CcSEcCtD
Cabergoline—Insomnia—Rosuvastatin—atherosclerosis	0.00151	0.00326	CcSEcCtD
Cabergoline—Ill-defined disorder—Simvastatin—atherosclerosis	0.00151	0.00325	CcSEcCtD
Cabergoline—Arrhythmia—Pravastatin—atherosclerosis	0.00151	0.00325	CcSEcCtD
Cabergoline—Palpitations—Ezetimibe—atherosclerosis	0.00151	0.00325	CcSEcCtD
Cabergoline—Paraesthesia—Rosuvastatin—atherosclerosis	0.0015	0.00324	CcSEcCtD
Cabergoline—Alopecia—Pravastatin—atherosclerosis	0.00149	0.00321	CcSEcCtD
Cabergoline—HTR7—cardiovascular system—atherosclerosis	0.00149	0.0141	CbGeAlD
Cabergoline—Arthralgia—Lovastatin—atherosclerosis	0.00148	0.00319	CcSEcCtD
Cabergoline—Anxiety—Lovastatin—atherosclerosis	0.00147	0.00318	CcSEcCtD
Cabergoline—Dyspepsia—Rosuvastatin—atherosclerosis	0.00147	0.00317	CcSEcCtD
Cabergoline—Hypertension—Ezetimibe—atherosclerosis	0.00147	0.00317	CcSEcCtD
Cabergoline—Flatulence—Niacin—atherosclerosis	0.00147	0.00317	CcSEcCtD
Cabergoline—Malaise—Simvastatin—atherosclerosis	0.00147	0.00316	CcSEcCtD
Cabergoline—Tension—Niacin—atherosclerosis	0.00146	0.00316	CcSEcCtD
Cabergoline—Discomfort—Lovastatin—atherosclerosis	0.00146	0.00315	CcSEcCtD
Cabergoline—Vertigo—Simvastatin—atherosclerosis	0.00146	0.00315	CcSEcCtD
Cabergoline—Arthralgia—Ezetimibe—atherosclerosis	0.00145	0.00313	CcSEcCtD
Cabergoline—Nervousness—Niacin—atherosclerosis	0.00145	0.00312	CcSEcCtD
Cabergoline—Flatulence—Pravastatin—atherosclerosis	0.00145	0.00312	CcSEcCtD
Cabergoline—Dry mouth—Lovastatin—atherosclerosis	0.00145	0.00312	CcSEcCtD
Cabergoline—Tension—Pravastatin—atherosclerosis	0.00144	0.00311	CcSEcCtD
Cabergoline—ADRA1A—cardiovascular system—atherosclerosis	0.00144	0.0136	CbGeAlD
Cabergoline—Muscle spasms—Niacin—atherosclerosis	0.00143	0.00309	CcSEcCtD
Cabergoline—Discomfort—Ezetimibe—atherosclerosis	0.00143	0.00309	CcSEcCtD
Cabergoline—Constipation—Rosuvastatin—atherosclerosis	0.00143	0.00308	CcSEcCtD
Cabergoline—Pain—Rosuvastatin—atherosclerosis	0.00143	0.00308	CcSEcCtD
Cabergoline—Confusional state—Lovastatin—atherosclerosis	0.00143	0.00308	CcSEcCtD
Cabergoline—Nervousness—Pravastatin—atherosclerosis	0.00143	0.00308	CcSEcCtD
Cabergoline—Dry mouth—Ezetimibe—atherosclerosis	0.00142	0.00306	CcSEcCtD
Cabergoline—Muscle spasms—Pravastatin—atherosclerosis	0.00141	0.00304	CcSEcCtD
Cabergoline—Confusional state—Ezetimibe—atherosclerosis	0.0014	0.00302	CcSEcCtD
Cabergoline—Arthralgia—Simvastatin—atherosclerosis	0.00138	0.00298	CcSEcCtD
Cabergoline—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00138	0.00297	CcSEcCtD
Cabergoline—Anxiety—Simvastatin—atherosclerosis	0.00138	0.00297	CcSEcCtD
Cabergoline—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.00137	0.00295	CcSEcCtD
Cabergoline—Discomfort—Simvastatin—atherosclerosis	0.00137	0.00295	CcSEcCtD
Cabergoline—Ill-defined disorder—Pravastatin—atherosclerosis	0.00136	0.00294	CcSEcCtD
Cabergoline—Anorexia—Lovastatin—atherosclerosis	0.00135	0.00291	CcSEcCtD
Cabergoline—Vertigo—Niacin—atherosclerosis	0.00134	0.00289	CcSEcCtD
Cabergoline—Syncope—Niacin—atherosclerosis	0.00134	0.00288	CcSEcCtD
Cabergoline—Confusional state—Simvastatin—atherosclerosis	0.00134	0.00288	CcSEcCtD
Cabergoline—Oedema—Simvastatin—atherosclerosis	0.00133	0.00286	CcSEcCtD
Cabergoline—Malaise—Pravastatin—atherosclerosis	0.00132	0.00286	CcSEcCtD
Cabergoline—Abdominal pain—Rosuvastatin—atherosclerosis	0.00132	0.00285	CcSEcCtD
Cabergoline—Vertigo—Pravastatin—atherosclerosis	0.00132	0.00285	CcSEcCtD
Cabergoline—Palpitations—Niacin—atherosclerosis	0.00132	0.00284	CcSEcCtD
Cabergoline—Loss of consciousness—Niacin—atherosclerosis	0.00131	0.00283	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.00129	0.00278	CcSEcCtD
Cabergoline—Insomnia—Lovastatin—atherosclerosis	0.00128	0.00276	CcSEcCtD
Cabergoline—Paraesthesia—Lovastatin—atherosclerosis	0.00127	0.00274	CcSEcCtD
Cabergoline—Arthralgia—Niacin—atherosclerosis	0.00127	0.00274	CcSEcCtD
Cabergoline—Hypertension—Pravastatin—atherosclerosis	0.00127	0.00273	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.00127	0.00273	CcSEcCtD
Cabergoline—ADRA1A—adipose tissue—atherosclerosis	0.00127	0.012	CbGeAlD
Cabergoline—Anorexia—Simvastatin—atherosclerosis	0.00126	0.00273	CcSEcCtD
Cabergoline—Dyspnoea—Lovastatin—atherosclerosis	0.00126	0.00272	CcSEcCtD
Cabergoline—Insomnia—Ezetimibe—atherosclerosis	0.00126	0.00271	CcSEcCtD
Cabergoline—ADRA2A—connective tissue—atherosclerosis	0.00126	0.0119	CbGeAlD
Cabergoline—Arthralgia—Pravastatin—atherosclerosis	0.00125	0.0027	CcSEcCtD
Cabergoline—Paraesthesia—Ezetimibe—atherosclerosis	0.00125	0.00269	CcSEcCtD
Cabergoline—Dyspepsia—Lovastatin—atherosclerosis	0.00125	0.00269	CcSEcCtD
Cabergoline—Anxiety—Pravastatin—atherosclerosis	0.00125	0.00269	CcSEcCtD
Cabergoline—Dry mouth—Niacin—atherosclerosis	0.00124	0.00268	CcSEcCtD
Cabergoline—Dyspnoea—Ezetimibe—atherosclerosis	0.00124	0.00267	CcSEcCtD
Cabergoline—Discomfort—Pravastatin—atherosclerosis	0.00124	0.00266	CcSEcCtD
Cabergoline—Hypersensitivity—Rosuvastatin—atherosclerosis	0.00123	0.00266	CcSEcCtD
Cabergoline—Decreased appetite—Lovastatin—atherosclerosis	0.00123	0.00266	CcSEcCtD
Cabergoline—Dyspepsia—Ezetimibe—atherosclerosis	0.00122	0.00264	CcSEcCtD
Cabergoline—Fatigue—Lovastatin—atherosclerosis	0.00122	0.00264	CcSEcCtD
Cabergoline—Oedema—Niacin—atherosclerosis	0.00122	0.00263	CcSEcCtD
Cabergoline—Constipation—Lovastatin—atherosclerosis	0.00121	0.00261	CcSEcCtD
Cabergoline—Pain—Lovastatin—atherosclerosis	0.00121	0.00261	CcSEcCtD
Cabergoline—Confusional state—Pravastatin—atherosclerosis	0.00121	0.00261	CcSEcCtD
Cabergoline—Decreased appetite—Ezetimibe—atherosclerosis	0.00121	0.00261	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.00121	0.0026	CcSEcCtD
Cabergoline—ADRA2C—adipose tissue—atherosclerosis	0.00121	0.0115	CbGeAlD
Cabergoline—Asthenia—Rosuvastatin—atherosclerosis	0.0012	0.00259	CcSEcCtD
Cabergoline—Insomnia—Simvastatin—atherosclerosis	0.0012	0.00259	CcSEcCtD
Cabergoline—Oedema—Pravastatin—atherosclerosis	0.0012	0.00258	CcSEcCtD
Cabergoline—Fatigue—Ezetimibe—atherosclerosis	0.0012	0.00258	CcSEcCtD
Cabergoline—Shock—Niacin—atherosclerosis	0.0012	0.00258	CcSEcCtD
Cabergoline—Paraesthesia—Simvastatin—atherosclerosis	0.00119	0.00257	CcSEcCtD
Cabergoline—Pain—Ezetimibe—atherosclerosis	0.00119	0.00256	CcSEcCtD
Cabergoline—Constipation—Ezetimibe—atherosclerosis	0.00119	0.00256	CcSEcCtD
Cabergoline—Pruritus—Rosuvastatin—atherosclerosis	0.00118	0.00255	CcSEcCtD
Cabergoline—Dyspnoea—Simvastatin—atherosclerosis	0.00118	0.00255	CcSEcCtD
Cabergoline—Hyperhidrosis—Niacin—atherosclerosis	0.00118	0.00254	CcSEcCtD
Cabergoline—Feeling abnormal—Lovastatin—atherosclerosis	0.00117	0.00252	CcSEcCtD
Cabergoline—Dyspepsia—Simvastatin—atherosclerosis	0.00117	0.00252	CcSEcCtD
Cabergoline—Anorexia—Niacin—atherosclerosis	0.00116	0.0025	CcSEcCtD
Cabergoline—Gastrointestinal pain—Lovastatin—atherosclerosis	0.00116	0.0025	CcSEcCtD
Cabergoline—Hyperhidrosis—Pravastatin—atherosclerosis	0.00116	0.0025	CcSEcCtD
Cabergoline—Decreased appetite—Simvastatin—atherosclerosis	0.00115	0.00249	CcSEcCtD
Cabergoline—Feeling abnormal—Ezetimibe—atherosclerosis	0.00115	0.00247	CcSEcCtD
Cabergoline—Diarrhoea—Rosuvastatin—atherosclerosis	0.00114	0.00247	CcSEcCtD
Cabergoline—Fatigue—Simvastatin—atherosclerosis	0.00114	0.00246	CcSEcCtD
Cabergoline—Anorexia—Pravastatin—atherosclerosis	0.00114	0.00246	CcSEcCtD
Cabergoline—Hypotension—Niacin—atherosclerosis	0.00114	0.00245	CcSEcCtD
Cabergoline—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.00114	0.00245	CcSEcCtD
Cabergoline—Constipation—Simvastatin—atherosclerosis	0.00113	0.00244	CcSEcCtD
Cabergoline—Pain—Simvastatin—atherosclerosis	0.00113	0.00244	CcSEcCtD
Cabergoline—Abdominal pain—Lovastatin—atherosclerosis	0.00112	0.00242	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Niacin—atherosclerosis	0.00111	0.00239	CcSEcCtD
Cabergoline—Dizziness—Rosuvastatin—atherosclerosis	0.00111	0.00238	CcSEcCtD
Cabergoline—Insomnia—Niacin—atherosclerosis	0.0011	0.00237	CcSEcCtD
Cabergoline—Abdominal pain—Ezetimibe—atherosclerosis	0.0011	0.00237	CcSEcCtD
Cabergoline—Paraesthesia—Niacin—atherosclerosis	0.00109	0.00236	CcSEcCtD
Cabergoline—Feeling abnormal—Simvastatin—atherosclerosis	0.00109	0.00236	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.00109	0.00235	CcSEcCtD
Cabergoline—Dyspnoea—Niacin—atherosclerosis	0.00109	0.00234	CcSEcCtD
Cabergoline—Gastrointestinal pain—Simvastatin—atherosclerosis	0.00108	0.00234	CcSEcCtD
Cabergoline—Insomnia—Pravastatin—atherosclerosis	0.00108	0.00234	CcSEcCtD
Cabergoline—Somnolence—Niacin—atherosclerosis	0.00108	0.00233	CcSEcCtD
Cabergoline—Paraesthesia—Pravastatin—atherosclerosis	0.00108	0.00232	CcSEcCtD
Cabergoline—Dyspepsia—Niacin—atherosclerosis	0.00107	0.00231	CcSEcCtD
Cabergoline—Dyspnoea—Pravastatin—atherosclerosis	0.00107	0.0023	CcSEcCtD
Cabergoline—HTR2A—connective tissue—atherosclerosis	0.00107	0.0101	CbGeAlD
Cabergoline—Decreased appetite—Niacin—atherosclerosis	0.00106	0.00228	CcSEcCtD
Cabergoline—Dyspepsia—Pravastatin—atherosclerosis	0.00106	0.00228	CcSEcCtD
Cabergoline—Rash—Rosuvastatin—atherosclerosis	0.00105	0.00227	CcSEcCtD
Cabergoline—Dermatitis—Rosuvastatin—atherosclerosis	0.00105	0.00227	CcSEcCtD
Cabergoline—Abdominal pain—Simvastatin—atherosclerosis	0.00105	0.00226	CcSEcCtD
Cabergoline—Headache—Rosuvastatin—atherosclerosis	0.00105	0.00226	CcSEcCtD
Cabergoline—Hypersensitivity—Lovastatin—atherosclerosis	0.00104	0.00225	CcSEcCtD
Cabergoline—Decreased appetite—Pravastatin—atherosclerosis	0.00104	0.00225	CcSEcCtD
Cabergoline—Pain—Niacin—atherosclerosis	0.00104	0.00224	CcSEcCtD
Cabergoline—Fatigue—Pravastatin—atherosclerosis	0.00103	0.00223	CcSEcCtD
Cabergoline—Constipation—Pravastatin—atherosclerosis	0.00103	0.00221	CcSEcCtD
Cabergoline—Pain—Pravastatin—atherosclerosis	0.00103	0.00221	CcSEcCtD
Cabergoline—Hypersensitivity—Ezetimibe—atherosclerosis	0.00102	0.00221	CcSEcCtD
Cabergoline—Asthenia—Lovastatin—atherosclerosis	0.00102	0.00219	CcSEcCtD
Cabergoline—Pruritus—Lovastatin—atherosclerosis	0.001	0.00216	CcSEcCtD
Cabergoline—Asthenia—Ezetimibe—atherosclerosis	0.000998	0.00215	CcSEcCtD
Cabergoline—Gastrointestinal pain—Niacin—atherosclerosis	0.000996	0.00215	CcSEcCtD
Cabergoline—Nausea—Rosuvastatin—atherosclerosis	0.000994	0.00214	CcSEcCtD
Cabergoline—Feeling abnormal—Pravastatin—atherosclerosis	0.000988	0.00213	CcSEcCtD
Cabergoline—Pruritus—Ezetimibe—atherosclerosis	0.000984	0.00212	CcSEcCtD
Cabergoline—Gastrointestinal pain—Pravastatin—atherosclerosis	0.00098	0.00211	CcSEcCtD
Cabergoline—Hypersensitivity—Simvastatin—atherosclerosis	0.000977	0.00211	CcSEcCtD
Cabergoline—Diarrhoea—Lovastatin—atherosclerosis	0.00097	0.00209	CcSEcCtD
Cabergoline—ADRA2A—adipose tissue—atherosclerosis	0.000963	0.00915	CbGeAlD
Cabergoline—Abdominal pain—Niacin—atherosclerosis	0.000962	0.00208	CcSEcCtD
Cabergoline—Asthenia—Simvastatin—atherosclerosis	0.000951	0.00205	CcSEcCtD
Cabergoline—Diarrhoea—Ezetimibe—atherosclerosis	0.000951	0.00205	CcSEcCtD
Cabergoline—Abdominal pain—Pravastatin—atherosclerosis	0.000948	0.00204	CcSEcCtD
Cabergoline—Pruritus—Simvastatin—atherosclerosis	0.000938	0.00202	CcSEcCtD
Cabergoline—Dizziness—Lovastatin—atherosclerosis	0.000937	0.00202	CcSEcCtD
Cabergoline—HTR2A—cardiovascular system—atherosclerosis	0.000929	0.00882	CbGeAlD
Cabergoline—HTR7—liver—atherosclerosis	0.000921	0.00875	CbGeAlD
Cabergoline—Dizziness—Ezetimibe—atherosclerosis	0.000919	0.00198	CcSEcCtD
Cabergoline—Diarrhoea—Simvastatin—atherosclerosis	0.000907	0.00196	CcSEcCtD
Cabergoline—Vomiting—Lovastatin—atherosclerosis	0.000901	0.00194	CcSEcCtD
Cabergoline—Hypersensitivity—Niacin—atherosclerosis	0.000897	0.00193	CcSEcCtD
Cabergoline—Rash—Lovastatin—atherosclerosis	0.000894	0.00193	CcSEcCtD
Cabergoline—Dermatitis—Lovastatin—atherosclerosis	0.000893	0.00193	CcSEcCtD
Cabergoline—ADRA1A—liver—atherosclerosis	0.000888	0.00844	CbGeAlD
Cabergoline—Headache—Lovastatin—atherosclerosis	0.000888	0.00191	CcSEcCtD
Cabergoline—Vomiting—Ezetimibe—atherosclerosis	0.000884	0.00191	CcSEcCtD
Cabergoline—Hypersensitivity—Pravastatin—atherosclerosis	0.000883	0.0019	CcSEcCtD
Cabergoline—Dizziness—Simvastatin—atherosclerosis	0.000877	0.00189	CcSEcCtD
Cabergoline—Rash—Ezetimibe—atherosclerosis	0.000877	0.00189	CcSEcCtD
Cabergoline—Dermatitis—Ezetimibe—atherosclerosis	0.000876	0.00189	CcSEcCtD
Cabergoline—Asthenia—Niacin—atherosclerosis	0.000874	0.00188	CcSEcCtD
Cabergoline—Headache—Ezetimibe—atherosclerosis	0.000871	0.00188	CcSEcCtD
Cabergoline—Pruritus—Niacin—atherosclerosis	0.000861	0.00186	CcSEcCtD
Cabergoline—Asthenia—Pravastatin—atherosclerosis	0.00086	0.00185	CcSEcCtD
Cabergoline—Pruritus—Pravastatin—atherosclerosis	0.000848	0.00183	CcSEcCtD
Cabergoline—ADRA2C—liver—atherosclerosis	0.000847	0.00804	CbGeAlD
Cabergoline—Vomiting—Simvastatin—atherosclerosis	0.000843	0.00182	CcSEcCtD
Cabergoline—Nausea—Lovastatin—atherosclerosis	0.000842	0.00182	CcSEcCtD
Cabergoline—Rash—Simvastatin—atherosclerosis	0.000836	0.0018	CcSEcCtD
Cabergoline—Dermatitis—Simvastatin—atherosclerosis	0.000835	0.0018	CcSEcCtD
Cabergoline—Diarrhoea—Niacin—atherosclerosis	0.000833	0.0018	CcSEcCtD
Cabergoline—Headache—Simvastatin—atherosclerosis	0.000831	0.00179	CcSEcCtD
Cabergoline—Nausea—Ezetimibe—atherosclerosis	0.000826	0.00178	CcSEcCtD
Cabergoline—Diarrhoea—Pravastatin—atherosclerosis	0.00082	0.00177	CcSEcCtD
Cabergoline—Dizziness—Niacin—atherosclerosis	0.000805	0.00174	CcSEcCtD
Cabergoline—Dizziness—Pravastatin—atherosclerosis	0.000793	0.00171	CcSEcCtD
Cabergoline—Nausea—Simvastatin—atherosclerosis	0.000788	0.0017	CcSEcCtD
Cabergoline—Vomiting—Niacin—atherosclerosis	0.000774	0.00167	CcSEcCtD
Cabergoline—Rash—Niacin—atherosclerosis	0.000768	0.00166	CcSEcCtD
Cabergoline—Dermatitis—Niacin—atherosclerosis	0.000767	0.00165	CcSEcCtD
Cabergoline—Headache—Niacin—atherosclerosis	0.000763	0.00164	CcSEcCtD
Cabergoline—Vomiting—Pravastatin—atherosclerosis	0.000762	0.00164	CcSEcCtD
Cabergoline—Rash—Pravastatin—atherosclerosis	0.000756	0.00163	CcSEcCtD
Cabergoline—Dermatitis—Pravastatin—atherosclerosis	0.000755	0.00163	CcSEcCtD
Cabergoline—Headache—Pravastatin—atherosclerosis	0.000751	0.00162	CcSEcCtD
Cabergoline—Nausea—Niacin—atherosclerosis	0.000723	0.00156	CcSEcCtD
Cabergoline—Nausea—Pravastatin—atherosclerosis	0.000712	0.00154	CcSEcCtD
Cabergoline—HTR2A—liver—atherosclerosis	0.000574	0.00546	CbGeAlD
Cabergoline—CYP3A4—liver—atherosclerosis	0.000532	0.00505	CbGeAlD
Cabergoline—HTR1D—Signaling Pathways—VEGFA—atherosclerosis	1.35e-05	3.24e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—SCARB1—atherosclerosis	1.35e-05	3.24e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—INS—atherosclerosis	1.35e-05	3.23e-05	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—STAT3—atherosclerosis	1.34e-05	3.23e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—MAPK8—atherosclerosis	1.34e-05	3.23e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling by GPCR—AKT1—atherosclerosis	1.34e-05	3.22e-05	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—STAT3—atherosclerosis	1.33e-05	3.21e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—IGF1—atherosclerosis	1.33e-05	3.2e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—NOS3—atherosclerosis	1.33e-05	3.19e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CCL2—atherosclerosis	1.32e-05	3.18e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—PIK3CG—atherosclerosis	1.32e-05	3.17e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—VEGFA—atherosclerosis	1.32e-05	3.17e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Metabolism—NOS3—atherosclerosis	1.31e-05	3.15e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—STAT3—atherosclerosis	1.31e-05	3.14e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—IGF1—atherosclerosis	1.3e-05	3.13e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—MMP9—atherosclerosis	1.3e-05	3.13e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—VEGFA—atherosclerosis	1.3e-05	3.12e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—CXCL8—atherosclerosis	1.29e-05	3.11e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—NFKB1—atherosclerosis	1.29e-05	3.1e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—STAT3—atherosclerosis	1.29e-05	3.09e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—MMP9—atherosclerosis	1.28e-05	3.09e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—MMP9—atherosclerosis	1.28e-05	3.09e-05	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—MAPK3—atherosclerosis	1.28e-05	3.08e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—SERPINE1—atherosclerosis	1.28e-05	3.08e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—CXCL8—atherosclerosis	1.28e-05	3.08e-05	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—MAPK3—atherosclerosis	1.28e-05	3.06e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—HMGCR—atherosclerosis	1.27e-05	3.06e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—NFKB1—atherosclerosis	1.27e-05	3.05e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—NFKB1—atherosclerosis	1.27e-05	3.05e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—MAPK8—atherosclerosis	1.27e-05	3.04e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—CXCL8—atherosclerosis	1.27e-05	3.04e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—MAPK3—atherosclerosis	1.27e-05	3.04e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling by GPCR—AKT1—atherosclerosis	1.26e-05	3.03e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—SERPINE1—atherosclerosis	1.26e-05	3.03e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—INS—atherosclerosis	1.25e-05	3.01e-05	CbGpPWpGaD
Cabergoline—ADRB1—GPCR downstream signaling—AKT1—atherosclerosis	1.25e-05	3e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—MAPK8—atherosclerosis	1.25e-05	3e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—MAPK8—atherosclerosis	1.25e-05	3e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—MAPK3—atherosclerosis	1.25e-05	3e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling by GPCR—AKT1—atherosclerosis	1.25e-05	2.99e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling by GPCR—AKT1—atherosclerosis	1.25e-05	2.99e-05	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—TGFB1—atherosclerosis	1.25e-05	2.99e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—VEGFA—atherosclerosis	1.24e-05	2.98e-05	CbGpPWpGaD
Cabergoline—ADRA2B—GPCR downstream signaling—AKT1—atherosclerosis	1.24e-05	2.98e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—CXCL8—atherosclerosis	1.24e-05	2.97e-05	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—TGFB1—atherosclerosis	1.24e-05	2.97e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—SERPINE1—atherosclerosis	1.24e-05	2.97e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—CXCL8—atherosclerosis	1.23e-05	2.96e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling by GPCR—IL6—atherosclerosis	1.23e-05	2.96e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CCL2—atherosclerosis	1.23e-05	2.96e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—MAPK3—atherosclerosis	1.23e-05	2.95e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—STAT3—atherosclerosis	1.23e-05	2.95e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—NOS3—atherosclerosis	1.23e-05	2.94e-05	CbGpPWpGaD
Cabergoline—ADRB2—GPCR downstream signaling—AKT1—atherosclerosis	1.22e-05	2.94e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling by GPCR—IL6—atherosclerosis	1.22e-05	2.93e-05	CbGpPWpGaD
Cabergoline—DRD5—Signaling Pathways—IL6—atherosclerosis	1.22e-05	2.92e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—TGFB1—atherosclerosis	1.21e-05	2.91e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—IGF1—atherosclerosis	1.21e-05	2.91e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—NOS3—atherosclerosis	1.21e-05	2.9e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling by GPCR—IL6—atherosclerosis	1.2e-05	2.89e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Metabolism—PTGS2—atherosclerosis	1.2e-05	2.88e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—CXCL8—atherosclerosis	1.2e-05	2.88e-05	CbGpPWpGaD
Cabergoline—HTR1A—GPCR downstream signaling—AKT1—atherosclerosis	1.2e-05	2.87e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—TGFB1—atherosclerosis	1.19e-05	2.86e-05	CbGpPWpGaD
Cabergoline—HTR2C—GPCR downstream signaling—AKT1—atherosclerosis	1.19e-05	2.86e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—NOS3—atherosclerosis	1.18e-05	2.84e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—CXCL8—atherosclerosis	1.18e-05	2.83e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling by GPCR—IL6—atherosclerosis	1.18e-05	2.83e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—MAPK3—atherosclerosis	1.17e-05	2.82e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling by GPCR—IL6—atherosclerosis	1.17e-05	2.81e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—MMP9—atherosclerosis	1.17e-05	2.81e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—VEGFA—atherosclerosis	1.17e-05	2.81e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—MMP9—atherosclerosis	1.16e-05	2.79e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—NFKB1—atherosclerosis	1.16e-05	2.78e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—STAT3—atherosclerosis	1.16e-05	2.78e-05	CbGpPWpGaD
Cabergoline—ADRA2C—GPCR downstream signaling—AKT1—atherosclerosis	1.16e-05	2.78e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—VEGFA—atherosclerosis	1.15e-05	2.77e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—VEGFA—atherosclerosis	1.15e-05	2.77e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—SERPINE1—atherosclerosis	1.15e-05	2.76e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—NFKB1—atherosclerosis	1.15e-05	2.76e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—MMP9—atherosclerosis	1.15e-05	2.75e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—STAT3—atherosclerosis	1.14e-05	2.74e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—STAT3—atherosclerosis	1.14e-05	2.74e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling by GPCR—IL6—atherosclerosis	1.14e-05	2.74e-05	CbGpPWpGaD
Cabergoline—ADRA1B—GPCR downstream signaling—AKT1—atherosclerosis	1.14e-05	2.74e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—MAPK8—atherosclerosis	1.14e-05	2.74e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—TGFB1—atherosclerosis	1.14e-05	2.73e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling by GPCR—AKT1—atherosclerosis	1.14e-05	2.73e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—ABCA1—atherosclerosis	1.13e-05	2.72e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—NFKB1—atherosclerosis	1.13e-05	2.72e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—MAPK8—atherosclerosis	1.13e-05	2.71e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling by GPCR—AKT1—atherosclerosis	1.13e-05	2.7e-05	CbGpPWpGaD
Cabergoline—DRD5—Signaling Pathways—AKT1—atherosclerosis	1.12e-05	2.7e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling by GPCR—IL6—atherosclerosis	1.12e-05	2.69e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—MMP9—atherosclerosis	1.12e-05	2.69e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—MMP9—atherosclerosis	1.11e-05	2.68e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—MAPK8—atherosclerosis	1.11e-05	2.68e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling by GPCR—AKT1—atherosclerosis	1.11e-05	2.67e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—NFKB1—atherosclerosis	1.11e-05	2.66e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—MAPK3—atherosclerosis	1.11e-05	2.66e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—NFKB1—atherosclerosis	1.1e-05	2.65e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—NOS3—atherosclerosis	1.1e-05	2.64e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—MAPK3—atherosclerosis	1.09e-05	2.62e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—MAPK3—atherosclerosis	1.09e-05	2.62e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—MAPK8—atherosclerosis	1.09e-05	2.62e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—CXCL8—atherosclerosis	1.09e-05	2.61e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling by GPCR—AKT1—atherosclerosis	1.09e-05	2.61e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—MMP9—atherosclerosis	1.08e-05	2.6e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—MAPK8—atherosclerosis	1.08e-05	2.6e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling by GPCR—AKT1—atherosclerosis	1.08e-05	2.6e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—TGFB1—atherosclerosis	1.07e-05	2.58e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—NFKB1—atherosclerosis	1.07e-05	2.58e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CXCL8—atherosclerosis	1.07e-05	2.57e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—MMP9—atherosclerosis	1.07e-05	2.56e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—TGFB1—atherosclerosis	1.06e-05	2.54e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—TGFB1—atherosclerosis	1.06e-05	2.54e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—NFKB1—atherosclerosis	1.06e-05	2.53e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—MAPK8—atherosclerosis	1.05e-05	2.53e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—VEGFA—atherosclerosis	1.05e-05	2.53e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling by GPCR—AKT1—atherosclerosis	1.05e-05	2.52e-05	CbGpPWpGaD
Cabergoline—DRD2—GPCR downstream signaling—AKT1—atherosclerosis	1.05e-05	2.52e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CXCL8—atherosclerosis	1.05e-05	2.52e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—VEGFA—atherosclerosis	1.04e-05	2.5e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—STAT3—atherosclerosis	1.04e-05	2.5e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—MAPK8—atherosclerosis	1.04e-05	2.49e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling by GPCR—AKT1—atherosclerosis	1.03e-05	2.48e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling by GPCR—IL6—atherosclerosis	1.03e-05	2.48e-05	CbGpPWpGaD
Cabergoline—HTR2A—GPCR downstream signaling—AKT1—atherosclerosis	1.03e-05	2.48e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—STAT3—atherosclerosis	1.03e-05	2.48e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—VEGFA—atherosclerosis	1.03e-05	2.47e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—STAT3—atherosclerosis	1.02e-05	2.45e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling by GPCR—IL6—atherosclerosis	1.02e-05	2.44e-05	CbGpPWpGaD
Cabergoline—ADRA1A—GPCR downstream signaling—AKT1—atherosclerosis	1.01e-05	2.43e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—VEGFA—atherosclerosis	1.01e-05	2.42e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—VEGFA—atherosclerosis	1e-05	2.4e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling by GPCR—IL6—atherosclerosis	9.96e-06	2.39e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—STAT3—atherosclerosis	9.96e-06	2.39e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—MAPK3—atherosclerosis	9.94e-06	2.39e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—STAT3—atherosclerosis	9.9e-06	2.38e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—MAPK3—atherosclerosis	9.85e-06	2.37e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—MMP9—atherosclerosis	9.83e-06	2.36e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—HMOX1—atherosclerosis	9.73e-06	2.34e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CXCL8—atherosclerosis	9.73e-06	2.34e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—VEGFA—atherosclerosis	9.73e-06	2.34e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—MAPK3—atherosclerosis	9.73e-06	2.34e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—NFKB1—atherosclerosis	9.73e-06	2.34e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—MMP9—atherosclerosis	9.67e-06	2.32e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—TGFB1—atherosclerosis	9.65e-06	2.32e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—STAT3—atherosclerosis	9.63e-06	2.31e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—VEGFA—atherosclerosis	9.58e-06	2.3e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—NFKB1—atherosclerosis	9.57e-06	2.3e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—MAPK8—atherosclerosis	9.56e-06	2.3e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—TGFB1—atherosclerosis	9.56e-06	2.3e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling by GPCR—AKT1—atherosclerosis	9.54e-06	2.29e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—MAPK3—atherosclerosis	9.51e-06	2.29e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—STAT3—atherosclerosis	9.48e-06	2.28e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—MMP9—atherosclerosis	9.47e-06	2.28e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—MAPK3—atherosclerosis	9.46e-06	2.27e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—TGFB1—atherosclerosis	9.44e-06	2.27e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—MAPK8—atherosclerosis	9.41e-06	2.26e-05	CbGpPWpGaD
Cabergoline—ADRA2A—GPCR downstream signaling—AKT1—atherosclerosis	9.4e-06	2.26e-05	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—IL6—atherosclerosis	9.38e-06	2.25e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling by GPCR—AKT1—atherosclerosis	9.38e-06	2.25e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—NFKB1—atherosclerosis	9.37e-06	2.25e-05	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—IL6—atherosclerosis	9.32e-06	2.24e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—APOB—atherosclerosis	9.32e-06	2.24e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—IL6—atherosclerosis	9.25e-06	2.22e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—TGFB1—atherosclerosis	9.23e-06	2.22e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—MAPK8—atherosclerosis	9.21e-06	2.21e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—MAPK3—atherosclerosis	9.2e-06	2.21e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling by GPCR—AKT1—atherosclerosis	9.19e-06	2.21e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—TGFB1—atherosclerosis	9.18e-06	2.21e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—IL6—atherosclerosis	9.13e-06	2.19e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—GSTM1—atherosclerosis	9.07e-06	2.18e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—MAPK3—atherosclerosis	9.06e-06	2.18e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—IL6—atherosclerosis	8.98e-06	2.16e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—TGFB1—atherosclerosis	8.93e-06	2.15e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—LPL—atherosclerosis	8.9e-06	2.14e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—VEGFA—atherosclerosis	8.83e-06	2.12e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—MMP9—atherosclerosis	8.8e-06	2.11e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—TGFB1—atherosclerosis	8.79e-06	2.11e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—STAT3—atherosclerosis	8.74e-06	2.1e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—NFKB1—atherosclerosis	8.71e-06	2.09e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—VEGFA—atherosclerosis	8.69e-06	2.09e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—GPX1—atherosclerosis	8.68e-06	2.09e-05	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—AKT1—atherosclerosis	8.66e-06	2.08e-05	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—AKT1—atherosclerosis	8.6e-06	2.07e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—STAT3—atherosclerosis	8.6e-06	2.07e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—IL6—atherosclerosis	8.58e-06	2.06e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—MAPK8—atherosclerosis	8.56e-06	2.06e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—AKT1—atherosclerosis	8.54e-06	2.05e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—VEGFA—atherosclerosis	8.51e-06	2.04e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—CD36—atherosclerosis	8.46e-06	2.03e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—STAT3—atherosclerosis	8.42e-06	2.02e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—AKT1—atherosclerosis	8.42e-06	2.02e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—MAPK3—atherosclerosis	8.35e-06	2.01e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—AKT1—atherosclerosis	8.29e-06	1.99e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—MAPK3—atherosclerosis	8.22e-06	1.97e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—TGFB1—atherosclerosis	8.1e-06	1.95e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—IL6—atherosclerosis	8.09e-06	1.94e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—MAPK3—atherosclerosis	8.05e-06	1.93e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—MTHFR—atherosclerosis	8.01e-06	1.93e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—IL6—atherosclerosis	7.98e-06	1.92e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—IL6—atherosclerosis	7.98e-06	1.92e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—TGFB1—atherosclerosis	7.97e-06	1.92e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—AKT1—atherosclerosis	7.91e-06	1.9e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—VEGFA—atherosclerosis	7.9e-06	1.9e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PPARA—atherosclerosis	7.86e-06	1.89e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—STAT3—atherosclerosis	7.82e-06	1.88e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—TGFB1—atherosclerosis	7.81e-06	1.88e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—AGT—atherosclerosis	7.61e-06	1.83e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—MAPK3—atherosclerosis	7.48e-06	1.8e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—AKT1—atherosclerosis	7.46e-06	1.79e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—APOE—atherosclerosis	7.46e-06	1.79e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Metabolism—AKT1—atherosclerosis	7.42e-06	1.78e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—CAV1—atherosclerosis	7.39e-06	1.78e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—APOA1—atherosclerosis	7.37e-06	1.77e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—AKT1—atherosclerosis	7.36e-06	1.77e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—AKT1—atherosclerosis	7.36e-06	1.77e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—IL6—atherosclerosis	7.27e-06	1.75e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—TGFB1—atherosclerosis	7.25e-06	1.74e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—IL6—atherosclerosis	7.2e-06	1.73e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—IL6—atherosclerosis	7.11e-06	1.71e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—IL6—atherosclerosis	6.95e-06	1.67e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—IL6—atherosclerosis	6.92e-06	1.66e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PIK3CG—atherosclerosis	6.73e-06	1.62e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—IL6—atherosclerosis	6.73e-06	1.62e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—AKT1—atherosclerosis	6.71e-06	1.61e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—AKT1—atherosclerosis	6.65e-06	1.6e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—IL6—atherosclerosis	6.62e-06	1.59e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—AKT1—atherosclerosis	6.56e-06	1.58e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PPARG—atherosclerosis	6.5e-06	1.56e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—AKT1—atherosclerosis	6.42e-06	1.54e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—AKT1—atherosclerosis	6.38e-06	1.53e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—INS—atherosclerosis	6.37e-06	1.53e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—AKT1—atherosclerosis	6.21e-06	1.49e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—AKT1—atherosclerosis	6.11e-06	1.47e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—IL6—atherosclerosis	6.11e-06	1.47e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Metabolism—AKT1—atherosclerosis	6.03e-06	1.45e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—IL6—atherosclerosis	6.01e-06	1.44e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—IL6—atherosclerosis	5.88e-06	1.41e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—ALB—atherosclerosis	5.84e-06	1.4e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—AKT1—atherosclerosis	5.63e-06	1.35e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—NOS3—atherosclerosis	5.59e-06	1.34e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—AKT1—atherosclerosis	5.54e-06	1.33e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—IL6—atherosclerosis	5.47e-06	1.31e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—AKT1—atherosclerosis	5.43e-06	1.3e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PTGS2—atherosclerosis	5.11e-06	1.23e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—AKT1—atherosclerosis	5.04e-06	1.21e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—AKT1—atherosclerosis	2.57e-06	6.17e-06	CbGpPWpGaD
